VBL Therapeutics (Nasdaq: VBLT) is developing targeted therapies for immune-inflammatory diseases. VBL’s lead immunology product candidate VB-601 is a targeted antibody for immune-inflammatory applications expected to enter Phase 1 this year that has shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease.
Company Details
- Employees
- 14
- Founded
- 2000
- Address
- 8 Hasatat St., Modiin,israel 7178106,israel
- Phone
- 97236346450
- bu****@****lrx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.vblrx.com
- HQ
- Modiin, Israel
Vbl Therapeutics (Nasdaq:vblt) Questions
Vbl Therapeutics (Nasdaq:Vblt)'s helpline number is 97236346450
Vbl Therapeutics (Nasdaq:Vblt)'s website is http://www.vblrx.com
Vbl Therapeutics (Nasdaq:Vblt)'s LinkedIn profile is https://www.linkedin.com/company/vascular-biogenics-ltd-
Vbl Therapeutics (Nasdaq:Vblt) has
14 employees.
View email and phone details for 14
employees at Vbl Therapeutics (Nasdaq:Vblt).
Vbl Therapeutics (Nasdaq:Vblt)'s industry is
Biotechnology Research
Vbl Therapeutics (Nasdaq:Vblt)'s top competitors are
Gamida Cell Ltd.,
Immunai,
1e Therapeutics,
Mediwound,
Evogene,
Neurosense Therapeutics,
Polypid Ltd.,
Biolinerx,
Novolog - Delivering Health,
Cytoreason.
Vbl Therapeutics (Nasdaq:Vblt)'s support email address is businessdev@vblrx.com
Vbl Therapeutics (Nasdaq:Vblt)'s categories are Biotechnology Research
Vbl Therapeutics (Nasdaq:Vblt)'s founding year is 2000
